Hemogenyx Pharmaceuticals PLC Announces Single CBR Can Treat Multiple Viruses

Author's Avatar
Jan 09, 2023

LONDON, UK / ACCESSWIRE / January 9, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO, Financial) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor ("CBR") platform technology, designed to program immune cells to eliminate viral infections by destroying the viruses that cause them. The Company's scientists have identified a target protein that can be incorporated into a single multipurpose CBR-based therapeutic capable of treating multiple viruses that belong to different viral families, instead of having to make a separate CBR construct for every virus. Among them are Dengue, Ebola, Marburg, Zika and Chikungunya. These viruses are among the most dangerous to humans, causing serious and often fatal diseases, and for which few effective treatment options exist.